Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Health & Nutrition Systems

This article was originally published in The Tan Sheet

Executive Summary

West Palm Beach, Fla.-based firm will discontinue sales of ephedra products because supplier Garden State Nutritionals lost product liability insurance, HNS says Dec. 19. GSN reported in September plans to phase in ephedra-free offerings, but said it still intended to sell the botanical (1"The Tan Sheet" Sept. 9, 2002, p. 4). HNS expects an 18% drop in quarterly sales due to the announcement, noting 19% of 2002 sales came from ephedra-based products, such as Thin Tabs, Fat Cutter Plus. Company retains $10 mil. of liability insurance. Plans to release clinically-tested-for-safety ephedra product with single-dose packaging have been shelved, but firm may launch "after dust settles" on the ingredient...

You may also be interested in...



GSN ephedra insurance

Garden State Nutritionals will continue to carry product liability coverage for its ephedra products, contrary to a report in 1"The Tan Sheet" Dec. 23, 2002, In Brief. Although it retains insurance, Health & Nutrition Systems still plans to cease marketing ephedra supplements due to "overwhelming negative press" on herbal ingredient...

Chattem Exiting Ephedra Market With Dexatrim Reformulations

Chattem is getting out of the ephedra business and is set to ship three reformulated Dexatrim SKUs by the end of September

QUOTED. 3 April 2020. Minetta Liu.

Liquid biopsy start-up Grail Inc. announced that a study of almost 6,700 participants found that its blood test could detect more than 50 types of cancer with a low false-positive rate. See what Minetta Liu, study co-lead author and a Mayo Clinic professor of oncology, had to say about the research.

Topics

UsernamePublicRestriction

Register

PS094939

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel